The FNDC3B Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Burkitt’s lymphoma B lymphocyte line Raji. This product provides a heterogeneous pool of cells harboring targeted disruptions in the FNDC3B gene, enabling loss-of-function studies without clonal selection. The polyclonal nature captures diverse editing outcomes, offering a robust model to assess gene function in a population context reflecting the inherent variability of CRISPR-mediated gene disruption. This format is particularly suited for researchers seeking to rapidly evaluate phenotypic consequences of FNDC3B ablation in an immune cell background.
Raji cells originate from a patient with Burkitt’s lymphoma and are widely employed as a model system in immunology, hematological malignancies, and B cell biology. These cells exhibit characteristics of mature B lymphocytes and are permissive for Epstein-Barr virus infection, making them valuable for studying B cell receptor signaling, apoptosis, and viral oncogenesis. Their robust growth in suspension culture and established use in drug screening and functional genomics further enhance their utility for CRISPR-based genetic perturbation studies.
The FNDC3B gene encodes adropin, a secreted peptide hormone involved in metabolic and vascular homeostasis. Mechanistically, adropin binds to the putative receptor GPR19 and initiates downstream signaling through PIK3CA and AKT1, culminating in phosphorylation of NOS3 (eNOS) and increased nitric oxide (NO) production. This cascade promotes vasodilation and enhances insulin sensitivity via SLC2A4 (GLUT4) translocation. Upstream regulators such as PPARG, insulin, glucose, and nutritional status modulate FNDC3B expression, while VEGFR2 has been identified as an interacting partner, underscoring its integration within adipokine and insulin signaling networks.
In the context of Raji B lymphocytes, FNDC3B knockout provides a unique opportunity to explore the role of adropin signaling beyond endothelial cells. While adropin is primarily recognized for endothelial function and metabolic regulation, its receptor GPR19 and downstream effectors are expressed in various tissues, including immune cells. This model allows dissection of potential non-endothelial functions, such as adropin’s impact on lymphocyte metabolism, proliferation, or cytokine responses. Thus, it can help elucidate crosstalk between energy homeostasis and immune regulation in a cancer cell background.
This polyclonal knockout cell population is ideally suited for a range of biomedical research applications. It can be employed in metabolic disorder modeling, type 2 diabetes research, and endothelial dysfunction studies, particularly when combined with endothelial co-culture systems or conditioned media experiments. Representative assays include adropin ELISA to confirm loss of hormone secretion, Western blotting for phospho?AKT and phospho?eNOS to assess pathway activity, glucose uptake measurements, and flow cytometry for GLUT4 translocation. Additionally, these cells serve as a valuable tool for anti?obesity drug screening and investigating insulin?sensitizing compounds. For further technical details or personalized experimental consultation, please contact Ascent Research.
